Reading workstation for clinical contrast echocardiography

临床造影超声心动图读取工作站

• 批准号: 10547365
• 负责人: Jiri Sklenar
• 金额: $ 102.35万
• 依托单位: NARNAR, LLC
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-03-01 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10547365
• 关键词: Address; Angiography; Archives; Authorization documentation; Cardiovascular system; Chest Pain; Clinic; Clinical; Collaborations; Communities; Computer software; Contrast Echocardiography; Contrast Media; Coronary; Coronary Arteriosclerosis; Coronary artery; Data; Defect; Dependence; Development; Diagnosis; Diagnostic; Documentation; EFRAC; Echocardiography; Education; Educational Curriculum; Environment; Event; FDA approved; Feedback; Freezing; Functional disorder; Generations; Goals; Gold; Health Sciences; Heart Transplantation; Heart failure; Image; Institution; International; Manuals; Medical; Methods; Microcirculation; Microvascular Dysfunction; Myocardial; Myocardial Infarction; Myocardial Ischemia; Myocardial perfusion; Oregon; Patients; Perfusion; Phase; Population; Positron-Emission Tomography; Process; Production; Reading; Reporting; Software Design; Standardization; Structure; System; Techniques; Technology; Testing; TimeLine; Training; Travel; Universities; Vascular Diseases; Visualization; Visualization software; Woman; cardiac magnetic resonance imaging; comparative; design; digital; experience; model design; nuclear imaging; online tutorial; preservation; product development; prognostic; prototype; single photon emission computed tomography; software development; tool; ultrasound; usability; user-friendly

PROJECT SUMMARY Coronary microvascular dysfunction (MVD) is increasingly being appreciated as a part of the pathophysiology of a number of conditions including MINOCA (myocardial infarction with nonobstructive coronary arteries), heart transplant graft vasculopathy, and heart failure with preserved ejection fraction (HFpEF). Coronary MVD occurs more commonly in women and can result in chest pain due to myocardial ischemia despite the presence of normal or near normal coronary angiograms. Identifying MVD in patients remains challenging and results in delayed or missed diagnoses even though cardiovascular event rates in these conditions are similar to those with established coronary artery disease. Clinical tools are therefore needed to both rapidly and accurately detect these conditions. Echocardiographic imaging of the myocardial microcirculation using ultrasound contrast agents, referred to as myocardial contrast echocardiography (MCE), has decades of data demonstrating the diagnostic and prognostic benefit of MCE in evaluating patients with MVD. In many ways, MCE is the preferred method for perfusion assessment because it is more convenient, less expensive, and more available than comparative techniques of nuclear imaging (SPECT), positron emission tomography (PET), and cardiac MRI. However, the clinical use of MCE has been limited to only a handful of experts in the field due in large part to the perceived experience dependence of MCE interpretation. Currently, no widely available clinical tools exist to support MCE quantitative analysis and interpretation. A clinical gap exists between a proven echocardiographic technique and the technology necessary to apply MCE in an efficient, user friendly and standardized method. Narnar LLC is developing a user-friendly contrast echocardiography quantification and visualization software. This product is designed to overcome the existing critical limitations of MCE by enabling rapid interpretation. This new clinical tool will evaluate the myocardial flow-function relationship that is critical to identifying patients with MVD by using echocardiography. The overall aim of this phase II proposal is to productionize the prototype software into a comprehensive software solution that when integrated into the current workflows using already available technologies (ultrasound, FDA approved enhancing agents) will enable a cardiologist to confidently assess both function and perfusion by contrast echocardiography.

项目摘要 冠状动脉微血管功能障碍（MVD）被越来越多地被视为病理生理的一部分 许多疾病包括minoca（具有非刺激性冠状动脉的心肌梗塞），心脏 移植移植的血管病和心力衰竭，并具有保留的射血分数（HFPEF）。冠状动脉MVD发生 女性更常见，尽管存在 正常或接近正常的冠状动脉造影。确定患者的MVD仍然具有挑战性，并导致 即使在这些疾病中的心血管事件发生率类似于那些，延迟或错过的诊断也 患有已建立的冠状动脉疾病。因此，需要快速，准确地检测到临床工具 这些条件。使用超声对比度的心肌微循环的超声心动图成像 代理，称为心肌对比超声心动图（MCE），有数十年的数据证明了该数据 MCE在评估MVD患者中的诊断和预后益处。在许多方面，MCE是首选 灌注评估的方法是因为它更方便，更便宜，并且比 核成像（SPECT），正电子发射断层扫描（PET）和心脏MRI的比较技术。 但是，MCE的临床使用仅限于该领域的少数专家 MCE解释的经验依赖性。目前，尚无广泛可用的临床工具 支持MCE定量分析和解释。在经过验证的超声心动图之间存在临床差距 技术和以高效，用户友好和标准化方法应用MCE所需的技术。 Narnar LLC正在开发一种用户友好的对比度超声心动图定量和可视化软件。 该产品旨在通过启用快速解释来克服MCE的现有临界局限性。 这种新的临床工具将评估心肌流动关系，这对于识别患者至关重要 使用超声心动图的MVD。该第二阶段提案的总体目的是生产原型 软件成综合的软件解决方案，该解决方案已集成到当前的工作流程中 可用技术（超声，FDA批准的增强剂）将使心脏病专家自信 通过对比的超声心动图评估功能和灌注。